Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.50 |
| ▸ | KMT5A | Q9NQR1 | 6/20 | 0.44 |
| ▸ | HTR2A | P28223 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | PGK1 | P00558 | 1/20 | 0.39 |
| ▸ | CCR5 | P51681 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14027591 | 0.84 | KDM4E (0.47) | KDM4ETDP1KMT5ALMNANPSR1 | |
| SCHEMBL4823452 | 0.83 | UHRF1 (0.40) | KDM4ETDP1 | |
| SCHEMBL4823490 | 0.82 | SLC2A1 (0.42) | KDM4ETDP1HSD17B10 | |
| SCHEMBL4816277 | 0.78 | PGK1 (0.50) | KDM4ETDP1KMT5ANPSR1PGK1 | |
| SCHEMBL14027675 | 0.78 | POLB (0.36) | KDM4ETDP1POLBALDH1A1LMNA | |
| SCHEMBL14027673 | 0.77 | KDM4E (0.37) | KDM4ETDP1POLBALDH1A1LMNA | |
| SCHEMBL14027625 | 0.75 | PGK1 (0.43) | KDM4ETDP1KMT5APGK1 | |
| SCHEMBL14027680 | 0.75 | KDM4E (0.36) | KDM4ETDP1POLBALDH1A1LMNA | |
| SCHEMBL4824654 | 0.72 | KDM4E (0.44) | KDM4ETDP1ALDH1A1LMNACCR5 | |
| SCHEMBL5766953 | 0.71 | CHEK2 (0.39) | HTR2AALDH1A1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080269217-A1 | Melanocortin-4 receptor binding compounds and methods of use thereof | ORE PHARMACEUTICALS, INC. (US) | 2008-10-30 | — | — | US | disclosed |
| US-20080269217-A1 | Melanocortin-4 receptor binding compounds and methods of use thereof | ORE PHARMACEUTICALS, INC. (US) | 2008-10-30 | — | — | US | disclosed |
| US-7375125-B2 | Melanocortin-4 receptor binding compounds and methods of use thereof | ORE PHARMACEUTICALS, INC. (US) | 2008-05-20 | — | — | US | disclosed |
| US-7375125-B2 | Melanocortin-4 receptor binding compounds and methods of use thereof | ORE PHARMACEUTICALS, INC. (US) | 2008-05-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269217-A1 | Melanocortin-4 receptor binding compounds and methods of use thereof | MC4R, MC5R, MC3R | KDM4E 1351/4885TDP1 4856/4885KMT5A 1695/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.